The largest database of trusted experimental protocols

10 protocols using akta start

1

Nanoparticle Isolation and Purification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Firstly, 1–5 × 107 cells were harvested with 0.25% trypsin–EDTA (SLB57926) and washed with Phosphate Buffered Saline (PBS) (10010023, Gibco, Paisley, Scotland, UK). To disrupt the cells, they were resuspended in 5 mL PBS (10010023, Gibco, Paisley, Scotland, UK) and sonicated. Subsequently, the sonicated sample was recovered, transferred to the LiposoFast LF-50 (Avestin, York, UK) and extruded under compressed nitrogen through Nuclepore Track-Etch Membrane Whatman polycarbonate filters in a serial manner, i.e., starting with a 1.0 µm (110610, Whatman, Maidstone, UK) followed by 0.4 µm (110607, Whatman, Maidstone, UK), and finally four times through a 0.1 µm Whatman® Anodisc inorganic filter membrane (6809-6012,, Whatman, Maidstone, UK),) to yield a homogenous population size. The crude NV sample was loaded on the S400 high prep column (GE Healthcare, Uppsala, Sweden) using AKTAStart (GE Healthcare) with a 280 nm UV flow cell at 4 °C. The NVs-containing fractions were combined, filtered (0.45 µm), and concentrated with an Amicon Ultra-15 Centrifugal Filter with an Ultracel-100 membrane (UFC910024, Merck, Darmstadt, Germany). See Figure 1a for a schematic illustration of the process.
+ Open protocol
+ Expand
2

Isotopic Labeling and Chromatography Workflows

Check if the same lab product or an alternative is used in the 5 most similar protocols
Isotopically enriched chemical compounds, namely [15N]-NH4Cl, [13C]-glucose and 2H2O, were purchased from Cambridge Isotope Laboratories (Tewksbury, MA, USA). Chromatography columns HiTrap Heparin, HiTrap Q HP and Superdex 75 10/300 GL, the Peristaltic Pump P-1 and AKTA Start were from GE Healthcare (Little Chalfont, UK). Reagents for SDS-PAGE were from BioRad (Hercules, CA, USA). Dialysis membrane tube Spectra/Por of 3.5 kDa nominal cut-off was from Spectrum Laboratories (Los Angeles, CA, USA) and Amicon Ultra-4 or -15 centrifugal filters of 10 or 3 kDa nominal cut-off were from Millipore (Billerica, MA, USA). Unless otherwise described, all other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).
+ Open protocol
+ Expand
3

Recombinant LigB Protein Vaccine Production

Check if the same lab product or an alternative is used in the 5 most similar protocols
A recombinant protein fragment, (rLigB(131–645), from LigB (AAS69085) was selected for evaluation as a vaccine candidate in combination with the adjuvant aluminium hydroxide (Sigma-Aldrich, São Paulo, SP, Brazil). LigB(131–645), corresponding to nucleotides 391–1948 of ligB, was cloned, expressed and purified as described [22 (link)], with the following modifications. After induction of expression with IPTG, the E. coli BL21 Star (DE3) (Invitrogen, São Paulo, SP, Brazil) cells were harvested and lysed in equilibration buffer (8 M urea, 0.5 M NaCl, 20 mM Tris, 1 mM EDTA, 10 mM imidazole, pH 8.0) (Sigma-Aldrich), overnight at room temperature followed by centrifugation (10,000× g, 1 h, 4°C). The supernatant was applied to a nickel-charged HisTrap FF column (GE Healthcare, São Paulo, SP, Brazil) and rLigB(131–645) was purified by immobilized metal affinity chromatography (IMAC) using an automated system (AKTA Start, GE Healthcare). Bound, His-tagged proteins were washed with 15 column volumes of equilibration buffer and subsequently eluted over a 20 ml gradient using elution buffer (8 M urea, 0.5 M NaCl, 20 mM Tris, 1 mM EDTA, 500 mM imidazole, pH 8.0). The eluted rLigB(131–645) was dialyzed against PBS at 4°C for 24 h and stored at -80°C or 4°C.
+ Open protocol
+ Expand
4

Purification of Recombinant BcnA Protein

Check if the same lab product or an alternative is used in the 5 most similar protocols
Escherichia coli BL21 bacteria harboring pET28a-bcnA were grown for 3 h with 500 mM isopropyl thio-β-galactoside (ThermoFisher Scientific, United Kingdom) at 25°C; bacteria were harvested, resuspended in 50 mM phosphate buffer (PBS), pH 7.4 (Sigma-Aldrich, United Kingdom), with protease inhibitors (Roche Diagnostic GmBH, Germany), and lysed using a cell disruptor at 27 kpsi (Constant Systems). The lysate was cleared by centrifugation at 16,000 × g for 60 min at 4°C (Sorvall RC 6 Plus, Germany), and the supernatant was filtered through 0.2-μm in-line filters. The supernatant was passed through a HisTrap FF 5-ml column, using AKTA Start (GE Healthcare Bio-science, Sweden). The purified protein was detected by Coomassie blue staining following 16% SDS-PAGE and quantified by Bradford assay using bovine serum albumin (BSA) as standard.
+ Open protocol
+ Expand
5

Isolation of Extracellular Vesicles from CPC Cultures

Check if the same lab product or an alternative is used in the 5 most similar protocols
To isolate extracellular vesicles (EV), initially we collected serum-free CM after 24 h of CPC monoculture and EV were isolated by differential centrifugation (Beckmann Coulter LE-80K Optima), as described before (26 (link)). In short, CM was centrifuged by subsequently 2,000 x g, 10,000 x g and 100,000 x g steps. The resulting 100,000 x g pellet was resuspended in PBS and centrifuged again at 100,000 x g. The washed EV pellet was resuspended in a small volume of PBS and stored at 4°C until further use.
Subsequently, we also isolated EV using size-exclusion chromatography (SEC), as described before (26 (link)). Serum-free CM was collected after 24 h of CPC monoculture and was centrifuged at 2,000 x g to remove debris, after which it was filtered (0.45 μm). CM was then concentrated to 5 mL using 100-kDa molecular weight cut-off (MWCO) Amicon Ultra Centrifugal Filters (Merck Millipore). The concentrated CM was subsequently loaded onto a S400 highprep column (GE Healthcare, Uppsala, Sweden) using an AKTAStart (GE Healthcare) containing a 280 nm flow cell. The fractions containing EV were pooled, concentrated using 100 kDa MWCO Amicon Ultra Centrifugal Filters, and filtered (0.45 μm). The EV protein concentration was determined with the microBCA protein assay kit (Thermo Scientific). EV were stored at 4°C and added to the medium of hfCF-laden GelMA in a concentration of 3 μg/mL.
+ Open protocol
+ Expand
6

Purification and Mutagenesis of UbK1 Protein

Check if the same lab product or an alternative is used in the 5 most similar protocols
The coding sequence of ubk1 was amplified using primers listed in Table S1, cloned into pLATE52 (ThermoFisher Scientific, Waltham, MA), expressed in E. coli BL21 (DE3), and His-tag protein was purified using HPLC (AKTA Start, GE Healthcare, Chicago, IL) with His Trap FF (GE Healthcare). Lysis buffer for protein purification consisted of PBS with 10 mM imidazole, pH 8.0, and 1 mg/ml lysozyme. Wash buffer for HPLC was PBS with 20 mM imidazole, pH 8.0. Proteins were eluted in PBS with 250 mM imidazole, pH 8.0. The purity of each fraction was assessed by SDS-PAGE and Coomassie staining. Proteins were quantified using the Qubit protein assay (ThermoFisher). To generate substitutions in UbK1, the Q5 Site-Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA) was used with the primers listed in Table S1. RprY and mutant derivatives were purified as described previously (Shen et al., 2020 (link)).
+ Open protocol
+ Expand
7

Drug Loading and Purification of Extracellular Vesicles

Check if the same lab product or an alternative is used in the 5 most similar protocols
A
concentration of 5 × 1012 EVs (either total EVs or
CD81 + AP EVs) was diluted into 450 μL of fresh 1× PBS.
Dimethyl sulfoxide (DMSO) was added to the EVs to a final concentration
of 5% to facilitate drug solubility. Drugs were then incubated with
purified EVs at 4 °C for 24 h with continuous rocking. Doxorubicin
and paclitaxel Oregon Green 488 (Flutax-2, Invitrogen P22310) were
added to a final concentration of 64 ng/μL. For non-specific
membrane labels, the Vybrant CM Dil dye (ThermoFisher V22888) was
added to a final concentration of 10 μM. After incubation, the
EV mixtures were then loaded onto equilibrated Capto Core 700 HiTrap
columns (GE Healthcare 17-5481-51). Fractions were collected using
the AKTA Start (GE Healthcare 29022094-ECOMINSSW) into sterile 1.5
mL tubes. The settings used for fraction collection are outlined in Table S2.
Drug or membrane fluorophore
(DiI or CellMask) EV fractions were identified using the BMG LabTech
FluorStar Optima plate reader. Fractions were further validated for
the presence of EVs using nanoparticle tracking analysis (NTA—see
below). Fractions of high concentrations of EVs and fluorescence were
pooled together.
+ Open protocol
+ Expand
8

Purification of mHDM-FH Protein

Check if the same lab product or an alternative is used in the 5 most similar protocols
All proteins used in this study were produced essentially as previously outlined, i.e. hHDM-FH (53 (link)). Briefly, for mHDM-FH, a single stable expressing clone was selected for protein production and scaled up in static tissue culture before transfer to roller bottles for 10 days (in the absence of Hygromycin B). Cell debris was removed by centrifugation and supernatant was sterile-filtered prior to loading on a 2 ml HiTrap NHS-activated high-performance column (GE Healthcare), which had been previously coupled (following manufacturers guidance) with the anti-mFH monoclonal antibody 2A5 (gift from Prof C. Harris, Newcastle UK), using an AKTA START (GE Healthcare) at a flowrate of 1 ml/min. Washes of 10 column volumes were performed prior to elution. Elution was achieved using 0.1M Glycine (pH of 2.7) and eluate was collected into 1M Tris pH 9.0. All protein-containing fractions were then combined and buffer exchanged into PBS using a PD-10 column (GE Healthcare). Proteins were further polished using a gel filtration column (Superdex 600, GE Healthcare) equilibrated with PBS buffer with an ÄKTA Purifier set to a flow rate of 0.5ml/min. One ml fractions were collected and stored at -80°C until needed.
+ Open protocol
+ Expand
9

Purification of Anti-SARS-CoV-2 Antibodies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-S-IgGs and anti-RBD-IgGs were obtained using S-Sepharose and RBD-Sepharose on an Akta Start chromatograph (GE Life Sciences, New York, NY, USA) and as described in [46 (link)]. The sorbents with immobilized S-protein and RBD were prepared according to the standard protocol using CNBr Sepharose (GE Life Sciences, New York, NY, USA) and our previously published works [46 (link),63 (link)]. An equimolar mixture of 10 IgG preparations was applied to 3 mL of RBD-Sepharose pre-equilibrated with 50 mM Tris-HCl, pH 7.5, containing 0.15 M NaCl (TBS). The fraction eluted with the acidic buffer was neutralized by adding 1/10 v/v 1.0 M Tris-HCl, pH 8.8, and then dialyzed against 20 mM Tris-HCl, pH 7.5. The IgG fraction not bound to RBD-Sepharose was applied to a 10 mL S-Sepharose column pre-equilibrated with TBS. The IgGs were eluted with a two-step gradient: 50 mM Tris-HCl, pH 7.5, containing 1.0 M NaCl and 0.1 M Gly-HCl, pH 2.6. The resulting fraction was also dialyzed against 20 mM Tris-HCl, pH 7.5.
+ Open protocol
+ Expand
10

Purification of Recombinant Protein OecC

Check if the same lab product or an alternative is used in the 5 most similar protocols
The preparation of the soluble proteins from frozen cells was prepared as described previously. Purification of OecC his from the soluble proteins of E. coli BL21 was performed using a FPLC system (A ¨KTA start, GE Healthcare Life Sciences) at 4 C. A Ni 2+ -chelating Sepharose affinity column (Ni Sepharose 6 Fast Flow; 25-mL; GE Healthcare Life Sciences) was equilibrated with 150 mL of HEPES buffer (20 mM, pH 7.8) containing 0.25 M KCl (buffer A). The protein sample (100 mL of soluble protein fraction) was applied to the column, followed by washing with buffer A containing 0.15 M imidazole. The fusion protein was subsequently eluted with buffer A containing 0.35 M imidazole. The flowrate was 1 mL min -1 , and the eluate was collected in 2-mL fractions. The salts were removed from the combined active fractions by using a prepacked PD-10 desalting column (GE Healthcare Life Sciences).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!